Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Guidant v. St. Jude

This article was originally published in The Gray Sheet

Executive Summary

Overturned $140 mil. implantable cardiac defibrillator patent infringement damage award to Guidant will likely be appealed, according to St. Jude. Filed by Guidant in November 1996 in Indianapolis federal court, the complaint currently focuses on two Guidant ICD patents ('472 and '288). Judge David Hamilton ruled Feb. 13 that "both patents are invalid," St. Jude says. A jury awarded Guidant the damages in July 2001, after finding that St. Jude infringed the '472 patent, which expired March 4, but that it did not infringe the '288 patent; both had been ruled valid (1"The Gray Sheet" July 9, 2001, In Brief)...

You may also be interested in...



Boston Sci., St. Jude settle patent suits

Both firms appear to benefit from a settlement that resolves four patent disputes related to the firms' cardiac rhythm management and neuromodulation devices. According to the July 31 announcement, the companies also have reached an accord to limit legal parameters for two additional suits, one of which dates back to 1996 (1"The Gray Sheet" Feb. 18, 2002, In Brief). The agreement bars Boston Scientific from pursuing lost profits and caps royalties at 3% of revenue from sales found to have infringed the patent in question. The companies agreed to cross-license certain of their cardiac rhythm management and neuromodulation patents. St. Jude describes the cross-license agreements as "worldwide" and "royalty free" in a filing with the Securities & Exchange Commission...

Guidant v. St. Jude

Guidant wins appeal from Washington, D.C. federal court to reinstate the validity of a defibrillator patent it claims St. Jude Medical infringed and return the case to the lower court to determine infringement and damages. In February 2002, a federal district court judge overturned a July 2001 jury decision finding St. Jude liable for $140 mil. in damages for infringing Guidant patents (1"The Gray Sheet" Feb. 18, 2002, In Brief)...

Guidant v. St. Jude

St. Jude will seek to have a $140 mil. implantable defibrillator patent infringement damage award to Guidant reduced or set aside, the firm says July 3. Filed in November 1996 in Indianapolis federal court, the complaint focused on four Guidant ICD patents (1"The Gray Sheet" Dec. 11, 2000, p. 11). The jury found that St. Jude infringed Guidant's '472 patent, which expired March 4, but that it did not infringe the firm's '288 patent. Both were ruled to be valid. The court previously dismissed claims on a third patent ('191), although Guidant has appealed that decision. Guidant dropped claims involving a fourth patent, which expired in 1998 ('678). The jury's finding will have no impact on current or future ICD offerings, St. Jude maintains. Post-trial motions must be filed within 10 weeks

Latest Headlines
See All
UsernamePublicRestriction

Register

MT016123

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel